Smoldering systemic mastocytosisQ82.2

Author:Prof. Dr. med. Peter Altmeyer

All authors of this article

Last updated on: 17.02.2023

Dieser Artikel auf Deutsch

Synonym(s)

Mastocytosis Syndrome; Smoldering mastocytosis; Smoldering mastocytosis, smoldering systemic mastocytosis; SSM

Requires free registration (medical professionals only)

Please login to access all articles, images, and functions.

Our content is available exclusively to medical professionals. If you have already registered, please login. If you haven't, you can register for free (medical professionals only).


Requires free registration (medical professionals only)

Please complete your registration to access all articles and images.

To gain access, you must complete your registration. You either haven't confirmed your e-mail address or we still need proof that you are a member of the medical profession.

Finish your registration now

DefinitionThis section has been translated automatically.

In smoldering (systemic) mastocytosis, there is no skin involvement. The mast cell infiltrates are found exclusively in the bone marrow.

The original term "mastocytosis syndrome" was used for (systemic) mastocytosis in which no skin lesions were detectable. The term is no longer listed in more recent classifications.

In systemic mastocytoses (indolent systemic mastocytosis, aggressive systemic mastocytosis, mast cell leukemia), the skin is involved to varying degrees and frequency.

Clinical featuresThis section has been translated automatically.

Irrespective of their tryptase level, patients complain, in addition to pruritus, of non-specific symptoms such as gastrointestinal complaints (diarrhoea, abdominal cramps, nausea, vomiting), tachycardia, hypotension, cephalgia, muscle pain, bone pain, flushing, fatigue and diffuse neuropsychiatric disorders.

Up to 30% of patients have bone involvement (osteopenia, osteoporosis, osteosclerosis, The osseous cytokines RANKL (receptor activator of nuclear factor kappa B-ligand), OPG (osteoprotegerin) and SOST (sclerostin) are elevated in patients with ISM(indolent systemic mastocytosis) and may interfere with bone remodeling.

DiagnosisThis section has been translated automatically.

Corresponding to mastocytosis.

TherapyThis section has been translated automatically.

Corresponding to mastocytosis.

Progression/forecastThis section has been translated automatically.

Corresponding to mastocytosis.

Authors

Last updated on: 17.02.2023